Skip to main content
Clinical Trials/NCT03384758
NCT03384758
Completed
Not Applicable

Evaluation of the Effect of Compression Therapy on the Microcirculation in Patients With Leg Edema and Mild to Moderate PAD or Diabetes Mellitus.

University Hospital Erlangen1 site in 1 country94 target enrollmentMay 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Peripheral Arterial Disease
Sponsor
University Hospital Erlangen
Enrollment
94
Locations
1
Primary Endpoint
Flow
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Aim of this prospective clinical study is the Evaluation of the Effect of Compression Therapy on the Microcirculation in Patients With Leg Edema and Mild to Moderate PAD or Diabetes Mellitus.

Detailed Description

Aim of this prospective clinical study is the Evaluation of the Effect of Compression Therapy on the Microcirculation in Patients With Leg Edema and Mild to Moderate PAD or Diabetes Mellitus. The microcirculation should be assessed by a combination of laserdoppler flowmetry and white light tissue spectrometry (O2C Device, Parameters sO2, Flow, rHb). By this, it is possible to detect the influence of the compression therapy on the skin microcirculation. Therefore, three study arms should be investigated, all patients clinically suffering under leg edema: healthy volunteers, patients with mild to moderate PAD and diabetics. All patients are recieveing compression therapy (Compression stockings class I for three hours, after a short break compression stockings class II for 3 hours) under Perfusion assessment control (O2C device).

Registry
clinicaltrials.gov
Start Date
May 1, 2018
End Date
March 1, 2019
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ulrich Rother

Principal investigator PD Dr. med. Ulrich Rother

University Hospital Erlangen

Eligibility Criteria

Inclusion Criteria

  • Study-Arm PAD:
  • leg edema
  • symptomatic PAD (Fontaine stage II)
  • no palpable foot pulses
  • ABI \<0.9 and \>0.6, absolute ankle pressure \> 60mmHg
  • Study-Arm Diabetes:
  • leg edema
  • Diabetes mellitus Typ 2 (history of longer than 2 years)
  • palpable foot pulses
  • Pallaesthesie \>6

Exclusion Criteria

  • Study-Arm PAD:
  • Critical limb ischemia
  • ABI \< 0.6
  • simoultaneous Diabetes Mellitus
  • Study-Arm Diabetes:
  • Wagner Score \>0
  • Pallasthesie \<6

Outcomes

Primary Outcomes

Flow

Time Frame: 12 Months

The Perfusion Situation should be recorded on the Level of Microcirculation by the Parameter Flow

Number of participants with treatment-related adverse events as assessed by questionnaire

Time Frame: 12 Months

The Adverse Events are defined in the questionnaire as: Abort of the Therapy, Pressure marks, Quantification of the wearing comfort (Points 1-10), subjective reduction of the leg edema (Points 1-10)

rHb

Time Frame: 12 Months

The Perfusion Situation should be recorded on the Level of Microcirculation by the Parameter rHb

sO2

Time Frame: 12 Months

The Perfusion Situation should be recorded on the Level of Microcirculation by the Parameter sO2

Study Sites (1)

Loading locations...

Similar Trials